TCGA-BH-A0C1-01B-11R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 47
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.420
- ANDROGEN_RESPONSE+0.400
- NOTCH_SIGNALING+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- PROTEIN_SECRETION+0.330
- MITOTIC_SPINDLE+0.300
- HEDGEHOG_SIGNALING+0.290
- TNFA_SIGNALING_VIA_NFKB+0.280
- G2M_CHECKPOINT+0.240
- WNT_BETA_CATENIN_SIGNALING+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.310
- DNA_REPAIR-0.260
- CHOLESTEROL_HOMEOSTASIS-0.220
- ADIPOGENESIS-0.190
- OXIDATIVE_PHOSPHORYLATION-0.170
- FATTY_ACID_METABOLISM-0.130
- BILE_ACID_METABOLISM-0.100
- KRAS_SIGNALING_DN-0.100
- P53_PATHWAY-0.090
- XENOBIOTIC_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.833 |
| 2 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.759 |
| 3 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.739 |
| 4 | TCGA-CV-7236-01A-11R-2016-07 | — | — | 0.734 |
| 5 | TCGA-AR-A24P-01A-11R-A169-07 | — | A | 0.733 |
| 6 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.728 |
| 7 | SJEPD032263_D1.RNA-Seq | EPN | Anaplastic EPN | 0.721 |
| 8 | SJEPD030782_D1.RNA-Seq | EPN | EPN Tumor | 0.708 |
| 9 | TCGA-A7-A26G-01A-21R-A169-07 | — | D | 0.702 |
| 10 | MDT-AP-3263 | Med | Medulloblastoma | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |